CLINICAL STUDY ON PROSTATIC CARCINOMA

Abstract

We clinically investigated 158 patients with prostatic carcinoma in whom the diagnosis was histologically confirmed. The patients were divided into a first-half group and a second-half group in relation to the 5-year period of the study. These was no difference in age between the two groups, but the clinical manifestations in the second-half group included of less urinary retention and more marked dysuria. In addition, the clinical stage C was significantly increased in the second-half group while G 1 showed a significant decrease. In regard to treatment, 153 patients (97%) received antiandrogenic therapy. Patients in the second-half group were less freqently treated by castration puls hormone administration, and LH-RH analogue therapy was used instead.
As the clinical stage progressed, the grading significantly increased, however, there were no differences the clinical staging and grading according to the clinical manifestations. The survival rate of G 1 patients was significantly higher than in the other three grades, but there were no differences in survival rate among G 2, G 3, and G 4. No cancer mortalities occurred in patients of clinical stage A, and there were no defferences in survival rate among the patients wirh clinical stage A, B, and C disease. Nevertheless, the survival rate in the clinical stage D patients was significantly lower than in the other three groups.
The presence or absence of metastasis was appeared to affect the prognosis of prostatic carcinoma.